Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol; Sarah Lévesque; Samuel T. Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R. Clements; Jean Eudes Fahrner; Laetitia Fend; John C. Bell; Karen L. Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1503032

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Medicine

Research output: Contribution to journal › Review article › peer-review

70 Citations (Scopus)

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Original language	English
Article number	e1503032
Journal	OncoImmunology
Volume	7
Issue number	12
DOIs	https://doi.org/10.1080/2162402X.2018.1503032
Publication status	Published - Dec 2 2018

Bibliographical note

Funding Information:
SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene.

Publisher Copyright:
© 2018, © 2018 Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

PubMed: MeSH publication types

Journal Article
Review
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402X.2018.1503032

Cite this

G. Pol, J., Lévesque, S., Workenhe, S. T., Gujar, S., Le Boeuf, F., R. Clements, D., Fahrner, J. E., Fend, L., C. Bell, J., L. Mossman, K., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018). Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 7(12), Article e1503032. https://doi.org/10.1080/2162402X.2018.1503032

@article{7f9acee98c254b8c8499968a869b8f4b,

title = "Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors",

abstract = "Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.",

author = "{G. Pol}, Jonathan and Sarah L{\'e}vesque and Workenhe, {Samuel T.} and Shashi Gujar and {Le Boeuf}, Fabrice and {R. Clements}, Derek and Fahrner, {Jean Eudes} and Laetitia Fend and {C. Bell}, John and {L. Mossman}, Karen and Jitka Fucikova and Radek Spisek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Funding Information: SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/2162402X.2018.1503032",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "12",

}

TY - JOUR

T1 - Trial Watch

T2 - Oncolytic viro-immunotherapy of hematologic and solid tumors

AU - G. Pol, Jonathan

AU - Lévesque, Sarah

AU - Workenhe, Samuel T.

AU - Gujar, Shashi

AU - Le Boeuf, Fabrice

AU - R. Clements, Derek

AU - Fahrner, Jean Eudes

AU - Fend, Laetitia

AU - C. Bell, John

AU - L. Mossman, Karen

AU - Fucikova, Jitka

AU - Spisek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

N1 - Funding Information: SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene. Publisher Copyright: © 2018, © 2018 Taylor & Francis Group, LLC.

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

AB - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85058014194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058014194&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1503032

DO - 10.1080/2162402X.2018.1503032

M3 - Review article

C2 - 30524901

AN - SCOPUS:85058014194

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 12

M1 - e1503032

ER -

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this